Terri B. Sebree - Jan 26, 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
President
Signature
/s/ Suzanne M. Hanlon, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jan 26, 2022
Transactions value $
$0
Form type
4
Date filed
1/28/2022, 03:14 PM
Next filing
Jul 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +85K +32.55% $0.00 346K Jan 26, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYNE Stock Option (right to buy) Award $0 +125K $0.00 125K Jan 26, 2022 Common Stock 125K $2.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date.
F2 The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.